Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Afinitor | Everolimus | Advanced Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Ibrance Resubmission | Palbociclib | Advanced breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | |||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Trisenox | Arsenic Trioxide | Acute Promyelocytic Leukemia | Reimburse | Complete | ||
Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
Idhifa | Enasidenib | Acute myeloid leukemia (AML) | Do not reimburse | Complete | ||
Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Reimburse | Complete | ||
Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Do not reimburse | Complete | ||
Vanflyta | quizartinib | acute myeloid leukemia (AML) | Pending |